YajC recognition of LdrA requires both transmembrane and cytoplasmic domains. by Yuto Nakamura (1493086)

Subjects:

LdrA expression causes transient growth arrest and the FLAG tag does not affect its toxicity. by Yuto Nakamura (1493086)

Subjects:

Inducible overexpression of YajC-HA. by Yuto Nakamura (1493086)

Subjects:

YajC Specifically Neutralizes Ldr Family Toxins. by Yuto Nakamura (1493086)

Subjects:

Controls for LdrA toxicity and recovery experiments. by Yuto Nakamura (1493086)

Subjects:

YajC co-expression does not alter the membrane localization or abundance of LdrA-FLAG. by Yuto Nakamura (1493086)

Subjects:

Genetic Screen Identifies YajC as an LdrA-Neutralizing Factor. by Yuto Nakamura (1493086)

Subjects:

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute My... by Amir T. Fathi (15313195)

Subjects:

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute My... by Amir T. Fathi (15313195)

Subjects:

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis by Nam Q. Bui (14958210)

Subjects:

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer by Steven B. Maron (15044607)

Subjects:

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBC... by Axel Stenmark Tullberg (15029928)

Subjects:

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer by Michelle L. Mierzwa (14963463)

Subjects:

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates by Evan C. Chen (15054014)

Subjects:

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates by Evan C. Chen (15054014)

Subjects:

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates by Evan C. Chen (15054014)

Subjects:

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates by Evan C. Chen (15054014)

Subjects:

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates by Evan C. Chen (15054014)

Subjects:

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates by Evan C. Chen (15054014)

Subjects:

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma by Srivandana Akshintala (16610490)

Subjects: